Sandy Spring Bank’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $3.1M | Buy |
6,391
+1,615
| +34% | +$753K | 0.13% | 140 |
|
|
2024
Q4 | $1.92M | Buy |
4,776
+3,621
| +314% | +$1.68M | 0.08% | 177 |
|
|
2024
Q3 | $537K | Buy |
1,155
+815
| +240% | +$391K | 0.02% | 282 |
|
|
2024
Q2 | $159K | Buy |
340
+37
| +12% | +$16.1K | 0.01% | 392 |
|
|
2024
Q1 | $127K | Buy |
303
+105
| +53% | +$44.4K | 0.01% | 420 |
|
|
2023
Q4 | $80.6K | Buy |
198
+181
| +1,065% | +$66.9K | ﹤0.01% | 479 |
|
|
2023
Q3 | $5.91K | Hold |
17
| – | – | ﹤0.01% | 904 |
|
|
2023
Q2 | $5.98K | Sell |
17
-61
| -78% | -$20.6K | ﹤0.01% | 933 |
|
|
2023
Q1 | $24.6K | Buy |
78
+71
| +1,014% | +$21.3K | ﹤0.01% | 663 |
|
|
2022
Q4 | $2.02K | Sell |
7
-16
| -70% | -$4.88K | ﹤0.01% | 1021 |
|
|
2022
Q3 | $7K | Buy |
23
+16
| +229% | +$4.6K | ﹤0.01% | 873 |
|
|
2022
Q2 | $2K | Hold |
7
| – | – | ﹤0.01% | 1063 |
|
|
2022
Q1 | $2K | Hold |
7
| – | – | ﹤0.01% | 1074 |
|
|
2021
Q4 | $2K | Sell |
7
-100
| -93% | -$19.4K | ﹤0.01% | 1158 |
|
|
2021
Q3 | $19K | Hold |
107
| – | – | ﹤0.01% | 772 |
|
|
2021
Q2 | $21K | Sell |
107
-6
| -5% | -$1.25K | ﹤0.01% | 775 |
|
|
2021
Q1 | $25K | Buy |
113
+7
| +7% | +$1.54K | ﹤0.01% | 641 |
|
|
2020
Q4 | $25K | Sell |
106
-194
| -65% | -$44.5K | ﹤0.01% | 607 |
|
|
2020
Q3 | $82K | Sell |
300
-14
| -4% | -$3.86K | 0.01% | 395 |
|
|
2020
Q2 | $91K | Hold |
314
| – | – | 0.01% | 374 |
|
|
2020
Q1 | $75K | Buy |
314
+14
| +5% | +$3.21K | 0.01% | 380 |
|
|
2019
Q4 | $66K | Hold |
300
| – | – | ﹤0.01% | 433 |
|
|
2019
Q3 | $51K | Hold |
300
| – | – | ﹤0.01% | 469 |
|
|
2019
Q2 | $55K | Sell |
300
-27
| -8% | -$4.72K | ﹤0.01% | 450 |
|
|
2019
Q1 | $60K | Buy |
327
+27
| +9% | +$4.99K | 0.01% | 422 |
|
|
2018
Q4 | $50K | Hold |
300
| – | – | ﹤0.01% | 450 |
|
|
2018
Q3 | $58K | Hold |
300
| – | – | ﹤0.01% | 443 |
|
|
2018
Q2 | $51K | Sell |
300
-46
| -13% | -$7.13K | ﹤0.01% | 462 |
|
|
2018
Q1 | $56K | Buy |
346
+300
| +652% | +$49K | 0.01% | 462 |
|
|
2017
Q4 | $7K | Buy |
+46
| New | +$6.81K | ﹤0.01% | 731 |
|
|
2017
Q1 | – | Sell |
-21
| Closed | -$2K | – | 875 |
|
|
2016
Q4 | $2K | Buy |
+21
| New | +$1.71K | ﹤0.01% | 821 |
|
|
2016
Q3 | – | Sell |
-42
| Closed | -$4K | – | 892 |
|
|
2016
Q2 | $4K | Hold |
42
| – | – | ﹤0.01% | 805 |
|
|
2016
Q1 | $3K | Sell |
42
-24
| -36% | -$2.17K | ﹤0.01% | 864 |
|
|
2015
Q4 | $8K | Buy |
66
+24
| +57% | +$2.9K | ﹤0.01% | 705 |
|
|
2015
Q3 | $4K | Hold |
42
| – | – | ﹤0.01% | 816 |
|
|
2015
Q2 | $5K | Buy |
+42
| New | +$5.29K | ﹤0.01% | 813 |
|
Other funds holding VRTX
Sandy Spring Bank's VRTX Position: Q1 2025 in Review
Sandy Spring Bank increased its Vertex Pharmaceuticals (VRTX) stake by 34% in Q1 2025, buying an estimated $753K and bringing the position to 6,391 shares worth $3.1M. The position accounts for 0.13% of the portfolio, ranked #140.
Sandy Spring Bank first reported a position in VRTX in Q2 2015 and has held it in 36 quarters since. 1,613 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.
- Sandy Spring Bank held 6,391 shares of Vertex Pharmaceuticals worth $3.1M as of Q1 2025.
- Sandy Spring Bank bought 1,615 Vertex Pharmaceuticals shares in Q1 2025, an estimated $753K.
- Vertex Pharmaceuticals made up 0.13% of Sandy Spring Bank's portfolio in Q1 2025, its #140 holding.
- Sandy Spring Bank first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 36 quarters since.
- 1,613 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.
Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.